1. Home
  2. CTNM vs EB Comparison

CTNM vs EB Comparison

Compare CTNM & EB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • EB
  • Stock Information
  • Founded
  • CTNM 2009
  • EB 2003
  • Country
  • CTNM United States
  • EB United States
  • Employees
  • CTNM N/A
  • EB N/A
  • Industry
  • CTNM
  • EB EDP Services
  • Sector
  • CTNM
  • EB Technology
  • Exchange
  • CTNM Nasdaq
  • EB Nasdaq
  • Market Cap
  • CTNM 248.7M
  • EB 261.5M
  • IPO Year
  • CTNM 2024
  • EB 2018
  • Fundamental
  • Price
  • CTNM $12.40
  • EB $3.05
  • Analyst Decision
  • CTNM Strong Buy
  • EB Buy
  • Analyst Count
  • CTNM 4
  • EB 2
  • Target Price
  • CTNM $22.75
  • EB $5.25
  • AVG Volume (30 Days)
  • CTNM 246.0K
  • EB 490.8K
  • Earning Date
  • CTNM 11-05-2025
  • EB 11-06-2025
  • Dividend Yield
  • CTNM N/A
  • EB N/A
  • EPS Growth
  • CTNM N/A
  • EB N/A
  • EPS
  • CTNM N/A
  • EB N/A
  • Revenue
  • CTNM N/A
  • EB $300,856,000.00
  • Revenue This Year
  • CTNM N/A
  • EB N/A
  • Revenue Next Year
  • CTNM N/A
  • EB $9.53
  • P/E Ratio
  • CTNM N/A
  • EB N/A
  • Revenue Growth
  • CTNM N/A
  • EB N/A
  • 52 Week Low
  • CTNM $3.35
  • EB $1.81
  • 52 Week High
  • CTNM $20.30
  • EB $4.12
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 69.65
  • EB 70.52
  • Support Level
  • CTNM $11.46
  • EB $2.69
  • Resistance Level
  • CTNM $13.09
  • EB $2.78
  • Average True Range (ATR)
  • CTNM 1.02
  • EB 0.10
  • MACD
  • CTNM -0.07
  • EB 0.03
  • Stochastic Oscillator
  • CTNM 74.89
  • EB 91.26

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About EB Eventbrite Inc.

Eventbrite Inc is a self-service ticketing and experience technology platform that serves event creators. The company's two-sided marketplace connects creators and consumers every month to share their passions, artistry, and causes through live experiences. Creators use its self-service ticketing and marketing tools to plan, promote, and sell tickets to their events, and event seekers use its website and mobile application to discover and purchase tickets to experiences. Geographically, it generates maximum revenue from the United States. The company generates revenues principally from service fees and payment processing fees from the sale of paid tickets on its platform.

Share on Social Networks: